Medical marijuana stocks have been all the rage and CARA has been lumped into that category, but the story is much deeper. Dr. Derek Chalmer, CEO of Cara Therapeutics joins Jill Malandrino at the NASDAQ MarketSite to give a complete review of the company. The company's lead program is an opiate-based program with the promise of analgesia with no narcotic side effects. CARA's main focus is obtaining approval for the first medications for 2016.

More from Video

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Video: Jim Cramer on Rising Interest Rates, Trade Worries & Caterpillar

Video: Jim Cramer on Rising Interest Rates, Trade Worries & Caterpillar

Jim Cramer: Hasbro Told You They Weren't Going to Make the Quarter

Jim Cramer: Hasbro Told You They Weren't Going to Make the Quarter

Jim Cramer: Tariffs and 3% Yield Obsession Are Preventing Stocks From Rising

Jim Cramer: Tariffs and 3% Yield Obsession Are Preventing Stocks From Rising

Video: Rising 10-Year Yields Don't Necessarily Make Stocks Less Attractive

Video: Rising 10-Year Yields Don't Necessarily Make Stocks Less Attractive